186 related articles for article (PubMed ID: 37838774)
21. Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy.
Sata M; Suhara T; Walsh K
Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):309-16. PubMed ID: 10669625
[TBL] [Abstract][Full Text] [Related]
22. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
Davidson WF; Haudenschild C; Kwon J; Williams MS
J Immunol; 2002 Dec; 169(11):6218-30. PubMed ID: 12444127
[TBL] [Abstract][Full Text] [Related]
23. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
Yamamoto TN; Lee PH; Vodnala SK; Gurusamy D; Kishton RJ; Yu Z; Eidizadeh A; Eil R; Fioravanti J; Gattinoni L; Kochenderfer JN; Fry TJ; Aksoy BA; Hammerbacher JE; Cruz AC; Siegel RM; Restifo NP; Klebanoff CA
J Clin Invest; 2019 Feb; 129(4):1551-1565. PubMed ID: 30694219
[TBL] [Abstract][Full Text] [Related]
24. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
[TBL] [Abstract][Full Text] [Related]
25. Mutations in apoptosis genes: a pathogenetic factor for human disease.
Müllauer L; Gruber P; Sebinger D; Buch J; Wohlfart S; Chott A
Mutat Res; 2001 Jul; 488(3):211-31. PubMed ID: 11397650
[TBL] [Abstract][Full Text] [Related]
26. The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling.
Bosque A; Aguiló JI; Alava MA; Paz-Artal E; Naval J; Allende LM; Anel A
Blood; 2007 Feb; 109(4):1627-35. PubMed ID: 17062728
[TBL] [Abstract][Full Text] [Related]
27. Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth
Al Subeh ZY; Poschel DB; Redd PS; Klement JD; Merting AD; Yang D; Mehta M; Shi H; Colson YL; Oberlies NH; Pearce CJ; Colby AH; Grinstaff MW; Liu K
ACS Nano; 2022 Aug; 16(8):12695-12710. PubMed ID: 35939651
[TBL] [Abstract][Full Text] [Related]
28. The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.
Xu X; Qiu J; Sun Y
Hum Vaccin Immunother; 2017 Jul; 13(7):1548-1555. PubMed ID: 28272967
[TBL] [Abstract][Full Text] [Related]
29. Fas-FasL interaction in cytotoxic T cell-mediated vitiligo: The role of lesional expression of tumor necrosis factor-α and interferon-γ in Fas-mediated melanocyte apoptosis.
Jimbo H; Nagai H; Fujiwara S; Shimoura N; Nishigori C
Exp Dermatol; 2020 Jan; 29(1):61-70. PubMed ID: 31675451
[TBL] [Abstract][Full Text] [Related]
30. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.
O' Reilly LA; Tai L; Lee L; Kruse EA; Grabow S; Fairlie WD; Haynes NM; Tarlinton DM; Zhang JG; Belz GT; Smyth MJ; Bouillet P; Robb L; Strasser A
Nature; 2009 Oct; 461(7264):659-63. PubMed ID: 19794494
[TBL] [Abstract][Full Text] [Related]
31. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
32. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction.
Ju ST; Matsui K; Ozdemirli M
Int Rev Immunol; 1999; 18(5-6):485-513. PubMed ID: 10672498
[TBL] [Abstract][Full Text] [Related]
33. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
Bajgain P; Torres Chavez AG; Balasubramanian K; Fleckenstein L; Lulla P; Heslop HE; Vera J; Leen AM
Cancer Immunol Res; 2022 Nov; 10(11):1370-1385. PubMed ID: 36122411
[TBL] [Abstract][Full Text] [Related]
34. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia.
Lamy T; Liu JH; Landowski TH; Dalton WS; Loughran TP
Blood; 1998 Dec; 92(12):4771-7. PubMed ID: 9845544
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies.
Rodriguez-Garcia A; Sharma P; Poussin M; Boesteanu AC; Minutolo NG; Gitto SB; Omran DK; Robinson MK; Adams GP; Simpkins F; Powell DJ
Mol Ther; 2020 Feb; 28(2):548-560. PubMed ID: 31870622
[TBL] [Abstract][Full Text] [Related]
37. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells.
Benmebarek MR; Karches CH; Cadilha BL; Lesch S; Endres S; Kobold S
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875739
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis of bovine granulosa cells after serum withdrawal is mediated by Fas antigen (CD95) and Fas ligand.
Hu CL; Cowan RG; Harman RM; Porter DA; Quirk SM
Biol Reprod; 2001 Feb; 64(2):518-26. PubMed ID: 11159354
[TBL] [Abstract][Full Text] [Related]
39. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
40. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation.
Thomas LR; Johnson RL; Reed JC; Thorburn A
J Biol Chem; 2004 Dec; 279(50):52479-86. PubMed ID: 15452120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
